financetom
Business
financetom
/
Business
/
Update: Cenovus Proposal Boosts MEG Energy to $8.6 Billion; MEG Board Recommends Shareholders Approve Deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Cenovus Proposal Boosts MEG Energy to $8.6 Billion; MEG Board Recommends Shareholders Approve Deal
Oct 8, 2025 7:52 AM

10:14 AM EDT, 10/08/2025 (MT Newswires) -- Cenovus Energy ( CVE ) entered into an amending agreement Wednesday in respect of the arrangement agreement dated August 21, 2025 to acquire MEG Energy ( MEGEF ) , which is also a target for Strathcona Resources ( STHRF ) .

The MEG Board is recommending MEG Shareholders vote for the improved Cenovus transaction. The board previously rejected Strathcona's Sept. 8 announcement around an amended and extended offer to acquire MEG. Its amended offer equated to $30.86 per MEG Share and an 11% premium to the agreement entered into by MEG and Cenovus announced August 22, 2025, valued at $27.79 per MEG share, in each case based on the one-day volume-weighted average share prices of Strathcona and Cenovus September 5, 2025. That amended offer reflected a 10% increase to Strathcona's original offer, which was valued at $28.02 per MEG Share as of September 5, 2025.

The Canadian Press noted today's Cenovus proposal values MEG at about $8.6 billion, including assumed debt, up from its earlier offer valued at $7.9 billion. It also noted Strathcona already holds a 14.2% interest in the company, and is offering 0.80 of a share for each MEG share it does not already own. Under the Strathcona deal, MEG shareholders would own 43% of the new entity. SCR values MEG at $7.6 billion.

At last look, MEG was up 4.6%. CVE was down about 0.3%, while SCR was up about 0.1%.

Under the terms of the amended Cenovus agreement today, each MEG shareholder will have the option to elect to receive, for each MEG common share, $29.50 in cash; or 1.240 Cenovus common shares, subject to rounding and pro-ration based on a maximum amount of $3.8 billion in cash and a maximum of 157.7 million Cenovus common shares. The pro-rated consideration represents a mix of 50% cash and 50% Cenovus common shares. On a fully pro-rated basis, the consideration per MEG common share represents approximately $14.75 in cash and 0.620 of a Cenovus common share.

The fully pro-rated consideration for MEG represents a value of approximately $29.80 per MEG share at Cenovus's closing share price October 7, 2025, an increase of approximately $1.32 per share based on current market pricing relative to the terms of the original arrangement agreement.

Cenovus in a statement said the consideration under the amended agreement represents Cenovus's best and final offer for MEG.

"We received support from the majority of MEG's shareholders for our transaction. However, many MEG shareholders indicated that they would prefer to receive greater Cenovus share consideration, so that they can more fully participate in the upside of the combined company," said Jon McKenzie, Cenovus president and chief executive officer.

"We listened to these comments and have changed the consideration under our offer to a maximum of 50% cash and 50% Cenovus shares, while increasing the aggregate purchase price. We believe this Amended Agreement delivers compelling and superior value to MEG shareholders and we encourage every MEG shareholder to vote their shares in favour."

In consideration of Cenovus amending and increasing the consideration for MEG, MEG and Cenovus have also amended the terms of the existing standstill agreement between the parties to allow Cenovus to complete purchases of up to 9.9% of MEG's outstanding common shares. To the extent Cenovus is able, the company intends to vote any acquired shares in favour of the transaction.

As a result of the lower maximum cash consideration to be issued under the amended agreement, if the transaction is approved by MEG shareholders, Cenovus intends to increase planned share repurchases over the coming quarters.

To allow MEG shareholders time to consider and vote on the amended agreement, the special meeting of MEG shareholders scheduled for October 9, 2025 has been postponed to October 22, 2025 at 9am MT (11am ET).

Cenovus confirms that key regulatory approvals have been received from the Canadian Competition Bureau and the United States Federal Trade Commission in respect of the transaction.

Meanwhile, Cenovus said in the third quarter it achieved record quarterly production in its upstream business and record crude throughput in its downstream business. Total upstream production was approximately 832,000 barrels of oil equivalent per day (BOE/d) in the third quarter, including record production of approximately 640,000 barrels per day (bbls/d) from the Oil Sands segment. Total downstream crude throughput was approximately 712,000 bbls/d in the third quarter, including approximately 606,000 bbls/d in U.S. Refining, representing total Downstream utilization of 98.8%.

Cenovus said its major growth projects continue to "progress well and on schedule", with volumes ramping up at Narrows Lake, first oil from the Foster Creek Optimization project expected in early 2026 and first oil from West White Rose expected in Q2 2026.

Cenovus closed the previously announced sale of its 50% interest in WRB Refining (WRB) to Phillips 66, with cash proceeds of approximately $1.8 billion (including closing adjustments) received October 1, 2025. Net debt at the end of the quarter was approximately $5.3 billion prior to receipt of the cash proceeds from the sale of WRB, or approximately $3.5 billion after receipt of proceeds October 1.

In the month of September, Cenovus purchased approximately 21.5 million of its common shares for $512 million, at an average price of approximately $23.81 per share. This brings total purchases in the third quarter to approximately 40.4 million shares for $900 million, at an average price of approximately $22.31 per share. With net debt below the company's long-term target of $4 billion, Cenovus anticipates continued accelerated share repurchases in the coming months.

Price: 24.38, Change: +0.11, Percent Change: +0.45

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US natural gas pipeline ADCC begins commercial operations
US natural gas pipeline ADCC begins commercial operations
Jul 12, 2024
July 12 (Reuters) - Infrastructure firm WhiteWater said on Friday the ADCC pipeline in South Texas started commercial service on July 1, amid surging U.S. liquefied natural gas exports to global markets. The 40-mile pipeline has a capacity to transport about 1.7 billion cubic feet per day (bcfd) of natural gas to the Cheniere Corpus Christi Liquefaction facility from Whistler...
Correction: Ericsson's Q2 Loss Widens, Revenue Falls
Correction: Ericsson's Q2 Loss Widens, Revenue Falls
Jul 12, 2024
09:19 AM EDT, 07/12/2024 (MT Newswires) -- (Corrects the currency throughout the story.) Ericsson (ERIC) reported a Q2 loss Friday of 3.34 Swedish kronor ($0.32) per diluted share, widening from a loss of 0.21 kronor a year earlier. Analysts polled by Capital IQ expected earnings of 0.36 kronor. Revenue for the quarter ended June 30 was 59.85 billion kronor, down...
Fluent Enters Partnership With Hy-Vee; Shares Rise Pre-Bell
Fluent Enters Partnership With Hy-Vee; Shares Rise Pre-Bell
Jul 12, 2024
09:26 AM EDT, 07/12/2024 (MT Newswires) -- Fluent (FLNT) said Friday it has entered into a media partnership with US retailer Hy-Vee and its retail media network RedMedia. Under the deal, Hy-Vee's online customers will get post-purchase offers, Fluent said. Hy-Vee has over 500 locations including grocery stores, convenience stores, and wine and spirits stores in the Midwest, according to...
SeaStar Medical Begins Commercial Sale of Pediatric Acute Kidney Injury Treatment
SeaStar Medical Begins Commercial Sale of Pediatric Acute Kidney Injury Treatment
Jul 12, 2024
09:28 AM EDT, 07/12/2024 (MT Newswires) -- SeaStar Medical ( ICU ) reported Friday the first commercial sale of the Quelimmune pediatric product to its US distribution partner Nuwellis ( NUWE ) . The company said the US Food and Drug Administration has approved the device for treating pediatric acute kidney injury in patients weighing at least 10 kilograms and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved